Abstract | BACKGROUND: AIM: This study aims to evaluate the serum levels of MMP-9 in OSCC patients and healthy controls and to correlate with its clinicopathological staging. MATERIALS AND METHODS: This study included 40 individuals; 20 patients with OSCC and 20 healthy controls. MMP-9 was determined in serum samples utilizing enzyme-linked immunosorbent assays. RESULTS: Descriptive statistics showed that 90% of the patients included in the OSCC groups were above 40 years, and 85% were males. There was a significant increase in the serum level of MMP-9 in OSCC patients compared to healthy controls with a mean difference of +28% (393.21 pg/ml) and a significant p-value of 0.001. (1365.80 ±236.414 pg/ml vs 973.67 ± 83.416 pg/ml). There was a significant increase in the serum levels of MMP-9 among the tumor stages and nodal involvement with a significant p-value of 0.002 and 0.001. No significant association was found between the age and gender groups in OSCC patients and serum levels of MMP-9. CONCLUSION: MMP-9 was significantly increased in OSCC when compared to healthy controls. Hence, MMP-9 can be used as a prognostic indicator in assessing tumor staging and nodal involvement.
|
Authors | Georgia Benitha, Pratibha Ramani, Selvaraj Jayaraman, Abilasha R, Karthikeyan Ramalingam, Murugesan Krishnan |
Journal | Cureus
(Cureus)
Vol. 15
Issue 2
Pg. e34954
(Feb 2023)
ISSN: 2168-8184 [Print] United States |
PMID | 36938194
(Publication Type: Journal Article)
|
Copyright | Copyright © 2023, Benitha et al. |